{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:20:54Z","timestamp":1760300454523},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients treated for non-squamous (non-Sq) non-small cell lung cancer (NSCLC) often require repeat biopsies to determine the optimal subsequent treatment. However, the differences between rebiopsy and initial biopsy in terms of their diagnostic yields and their ability to test the molecular profiles using bronchoscopy with radial endobronchial ultrasound guidance in patients with advanced NSCLC remain unclear. Hence, we aimed to compare the diagnostic yields and ability for molecular analyses of rebiopsies with those of initial biopsies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We investigated 301 patients with advanced non-Sq NSCLC who underwent radial endobronchial ultrasound-guided transbronchial biopsy (TBB) for peripheral pulmonary lesions (PPLs) between August 2014 and July 2017. Patients were divided into the rebiopsy and initial biopsy groups: the latter referred to the biopsy that determined the definitive diagnosis. The diagnostic yields and ability for molecular analyses were compared between the two groups, and the factors affecting the TBB diagnostic yield were identified using univariate and multivariate analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The diagnostic yields of the rebiopsy and initial biopsy groups were comparable (86.8 and 90.8%, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.287). Furthermore, 93.0 and 94.0% of the patients in the rebiopsy and initial biopsy groups, respectively, had adequate specimens for gene profiling and mutational analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.765). The factors that increased the diagnostic yield were a positive bronchus sign (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and tumour location within the internal two-thirds of the lungs (<jats:italic>p<\/jats:italic>\u2009=\u20090.026).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The PPL diagnostic yield of the rebiopsy group was as high as that of the initial biopsy group. Hence, TBB for PPLs is feasible for patients requiring rebiopsy as well as for those with initial diagnoses. Adequate, high-quality biopsy specimens can be obtained by transbronchial rebiopsy for molecular testing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-020-01277-6","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T11:42:45Z","timestamp":1599738165000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The utility of transbronchial rebiopsy for peripheral pulmonary lesions in patients with advanced non-squamous non-small cell lung cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Akiko","family":"Tateishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Aoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"issue":"Suppl 2","key":"1277_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/0284186X.2016.1150608","volume":"55","author":"E Jakobsen","year":"2016","unstructured":"Jakobsen E, Rasmussen TR, Green A. Mortality and survival of lung cancer in Denmark: results from the Danish lung Cancer group 2000-2012. Acta Oncol. 2016;55(Suppl 2):2\u20139.","journal-title":"Acta Oncol"},{"key":"1277_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.resinv.2014.04.002","volume":"52","author":"N Sawabata","year":"2014","unstructured":"Sawabata N. Prognosis of lung cancer patients in Japan according to data from the Japanese joint Committee of Lung Cancer Registry. Respir Investig. 2014;52:317\u201321.","journal-title":"Respir Investig"},{"key":"1277_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92\u20138.","journal-title":"N Engl J Med"},{"key":"1277_CR4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1277_CR5","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330.","journal-title":"Lancet."},{"key":"1277_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129\u201339.","journal-title":"N Engl J Med"},{"key":"1277_CR7","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","volume":"363","author":"EL Kwak","year":"2010","unstructured":"Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693\u2013703.","journal-title":"N Engl J Med"},{"key":"1277_CR8","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","volume":"35","author":"SM Lim","year":"2017","unstructured":"Lim SM, Kim HR, Lee JS, et al. Phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613\u20138.","journal-title":"J Clin Oncol"},{"key":"1277_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017;18:1307\u201316.","journal-title":"Lancet Oncol"},{"key":"1277_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786\u201392.","journal-title":"N Engl J Med"},{"key":"1277_CR11","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Larriba JL, L\u00e1zaro-Quintela M, Cobo M, D\u00f3mine M, Majem M, Garc\u00eda-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl Lung Cancer Res 2017;6 (Suppl 1):S21\u2013S34. https:\/\/doi.org\/10.21037\/tlcr.2017.10.03.","DOI":"10.21037\/tlcr.2017.10.03"},{"key":"1277_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"},{"key":"1277_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21037\/tlcr.2016.12.02","volume":"5","author":"R Minari","year":"2016","unstructured":"Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5:695\u2013708.","journal-title":"Transl Lung Cancer Res."},{"key":"1277_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nature06915","volume":"452","author":"LJ van't Veer","year":"2008","unstructured":"van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452:564\u201370.","journal-title":"Nature."},{"key":"1277_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cncr.29089","volume":"121","author":"IS Hagemann","year":"2015","unstructured":"Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121:631\u20139.","journal-title":"Cancer."},{"key":"1277_CR16","doi-asserted-by":"publisher","first-page":"71013","DOI":"10.18632\/oncotarget.11717","volume":"7","author":"CW Bennett","year":"2016","unstructured":"Bennett CW, Berchem G, Kim YJ, El-Khoury V. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. Oncotarget. 2016;7:71013\u201335.","journal-title":"Oncotarget."},{"key":"1277_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/cas.12963","volume":"107","author":"T Kawamura","year":"2016","unstructured":"Kawamura T, Kenmotsu H, Taira T, et al. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. Cancer Sci. 2016;107:1001\u20135.","journal-title":"Cancer Sci"},{"key":"1277_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12890-016-0268-3","volume":"16","author":"T Izumo","year":"2016","unstructured":"Izumo T, Matsumoto Y, Chavez C, Tsuchida T. Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment. BMC Pulm Med. 2016;16:106.","journal-title":"BMC Pulm Med"},{"key":"1277_CR19","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","volume":"19","author":"T Kawamura","year":"2018","unstructured":"Kawamura T, Kenmotsu H, Omori S, et al. Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer. Clin Lung Cancer. 2018;19:e247\u201352.","journal-title":"Clin Lung Cancer"},{"key":"1277_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2016-000163","volume":"4","author":"H Ishii","year":"2017","unstructured":"Ishii H, Azuma K, Yamada K, et al. Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. BMJ Open Respir Res. 2017;4:e000163.","journal-title":"BMJ Open Respir Res"},{"key":"1277_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000431383","volume":"90","author":"M Hayama","year":"2015","unstructured":"Hayama M, Izumo T, Matsumoto Y, et al. Complications with Endobronchial ultrasound with a guide sheath for the diagnosis of peripheral pulmonary lesions. Respiration. 2015;90:129\u201335.","journal-title":"Respiration."},{"key":"1277_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/crj.12321","volume":"11","author":"Y Matsumoto","year":"2017","unstructured":"Matsumoto Y, Izumo T, Sasada S, et al. Diagnostic utility of endobronchial ultrasound with a guide sheath under the computed tomogramphy workstation (ziostation) for small peripheral pulmonary lesions. Clin Respir J. 2017;11:185\u201392.","journal-title":"Clin Respir J"},{"key":"1277_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1378\/chest.11-1764","volume":"142","author":"JS Wang Memoli","year":"2012","unstructured":"Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest. 2012;142:385\u201393.","journal-title":"Chest."},{"issue":"Suppl 10","key":"1277_CR24","doi-asserted-by":"publisher","first-page":"S1047","DOI":"10.21037\/jtd.2017.05.48","volume":"9","author":"SS Dhillon","year":"2017","unstructured":"Dhillon SS, Harris K. Bronchoscopy for the diagnosis of peripheral lung lesions. J Thorac Dis. 2017;9(Suppl 10):S1047\u201358.","journal-title":"J Thorac Dis"},{"key":"1277_CR25","doi-asserted-by":"crossref","first-page":"5048961","DOI":"10.1155\/2016\/5048961","volume":"2016","author":"MA De Roza","year":"2016","unstructured":"De Roza MA, Quah KH, Tay CK, et al. Diagnosis of peripheral lung lesions via conventional flexible bronchoscopy with multiplanar CT planning. Pulm Med. 2016;2016:5048961.","journal-title":"Pulm Med"},{"issue":"12","key":"1277_CR26","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/thx.2010.145490","volume":"66","author":"T Ishida","year":"2011","unstructured":"Ishida T, Asano F, Tamazaki K, et al. Virtual bronchoscopic navigateon combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial. Thorax. 2011;66(12):1072\u20137.","journal-title":"Thorax."},{"key":"1277_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.7150\/jca.21650","volume":"9","author":"EK Goag","year":"2018","unstructured":"Goag EK, Lee JM, Chung KS, et al. Usefulness of bronchoscopic rebiopsy of non-small cell lung cancer with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. J Cancer. 2018;9:1113\u201320.","journal-title":"J Cancer"},{"key":"1277_CR28","doi-asserted-by":"publisher","first-page":"28947","DOI":"10.3402\/ecrj.v2.28947","volume":"2","author":"A Durakovic","year":"2015","unstructured":"Durakovic A, Andersen H, Christiansen A, Hammen I. Retrospective analysis of radial EBUS outcome for the diagnosis of peripheral pulmonary lesion: sensitivity and complications. Eur Clin Respir J. 2015;2:28947.","journal-title":"Eur Clin Respir J"},{"key":"1277_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","volume":"86","author":"C Chouaid","year":"2015","unstructured":"Chouaid C, Dujon C, Do P, et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2015;86:170\u20133.","journal-title":"Lung Cancer"},{"key":"1277_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11523-014-0332-y","volume":"10","author":"C Bosc","year":"2015","unstructured":"Bosc C, Ferretti GR, Cadranel J, et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Target Oncol. 2015;10:247\u201353.","journal-title":"Target Oncol"},{"key":"1277_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"1277_CR32","doi-asserted-by":"crossref","unstructured":"Giroux-Leprieur E, Fallet V, Cadranel J, Wislez M. Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer (Auckl). 2016;7:83\u201390.","DOI":"10.2147\/LCTT.S99303"},{"key":"1277_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.jtho.2019.06.014","volume":"14","author":"X Rong","year":"2019","unstructured":"Rong X, Liang Y, Han Q, et al. Molecular mechanisms of tyrosine kinase inhibitor resistance induced by membranous\/cytoplasmic\/nuclear translocation of epidermal growth factor receptor. J Thorac Oncol. 2019;14:1766\u201383.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01277-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01277-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T23:14:52Z","timestamp":1631142892000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01277-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01277-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"23 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the National Cancer Center Institutional Review Board, and the requirement for informed consent was waived due to the retrospective observational nature (No. 2018\u2013090).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}